{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T05:05:11Z","timestamp":1733202311683,"version":"3.30.0"},"reference-count":40,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14795","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:08:46Z","timestamp":1731071326000},"source":"Crossref","is-referenced-by-count":0,"title":["Long\u2011term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report"],"prefix":"10.3892","volume":"29","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Huaihai Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Imaging, Huaihai Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Di","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"key20241202101942_b1-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"clinicalguidelines@esmo.org: Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"key20241202101942_b2-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20241202101942_b3-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: A retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"key20241202101942_b4-ol-29-1-14795","first-page":"545","article-title":"Neuroendocrine tumor management guidelines of the Chinese anti-cancer association (2022 Edition)","volume":"32","author":"Chinese Anti-Cancer Association Neuroendocrine Tumor Professional","year":"2022","journal-title":"China Oncology"},{"key":"key20241202101942_b5-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.3390\/jcm12155138","article-title":"A comprehensive review on neuroendocrine neoplasms: Presentation, pathophysiology and management","volume":"12","author":"Sultana","year":"2023","journal-title":"J Clin Med"},{"key":"key20241202101942_b6-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"key20241202101942_b7-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"key20241202101942_b8-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"\u00d6berg","year":"2012","journal-title":"Ann Oncol"},{"key":"key20241202101942_b9-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5603\/EP.2013.0031","article-title":"Pancreatic neuroendocrine neoplasms-management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)","volume":"64","author":"Kos-Kud\u0142a","year":"2013","journal-title":"Endokrynol Pol"},{"key":"key20241202101942_b10-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition ajcc cancer staging manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20241202101942_b11-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20241202101942_b12-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20241202101942_b13-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"key20241202101942_b14-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00268-015-3328-6","article-title":"Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrine tumor: A systematic review","volume":"40","author":"Jilesen","year":"2016","journal-title":"World J Surg"},{"key":"key20241202101942_b15-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"838103","DOI":"10.3389\/fonc.2022.838103","article-title":"The role of primary tumor resection in patients with pancreatic neuroendocrine tumors with liver metastases","volume":"12","author":"Mou","year":"2022","journal-title":"Front Oncol"},{"key":"key20241202101942_b16-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-med-042320-011248","article-title":"Progress in the management of pancreatic neuroendocrine tumors","volume":"73","author":"Chang","year":"2022","journal-title":"Ann Rev Med"},{"key":"key20241202101942_b17-ol-29-1-14795","first-page":"94","article-title":"Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association (2022)","volume":"14","author":"Liang","year":"2023","journal-title":"Medical Journal of Peking Union Medical College Hospital"},{"key":"key20241202101942_b18-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20241202101942_b19-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"key20241202101942_b20-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1056\/NEJMc2308037","article-title":"PD-1 and PD-L1 blockade plus chemotherapy in endometrial cancer","volume":"389","author":"Polak","year":"2023","journal-title":"N Engl J Med"},{"key":"key20241202101942_b21-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/ph14050476","article-title":"Activity and safety of immune checkpoint inhibitors in neuroendocrine neoplasms: A systematic review and meta-analysis","volume":"14","author":"Bongiovanni","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20241202101942_b22-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"941832","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20241202101942_b23-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"key20241202101942_b24-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20241202101942_b25-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.19.00980","article-title":"Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU study","volume":"37","author":"Carmona-Bayonas","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20241202101942_b26-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20241202101942_b27-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"New Engl J Med"},{"key":"key20241202101942_b28-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jncc.2022.08.006","article-title":"Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer","volume":"2","author":"Cui","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"key20241202101942_b29-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/eus.eus_28_19","article-title":"EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?","volume":"8","author":"Larghi","year":"2019","journal-title":"Endosc Ultrasound"},{"key":"key20241202101942_b30-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/den.14681","article-title":"Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis","volume":"36","author":"Khoury","year":"2024","journal-title":"Dig Endosc"},{"key":"key20241202101942_b31-ol-29-1-14795","first-page":"139","article-title":"A retrospective cohort study of Qizhen YiLiu prescription combined with somatostatin analogues in the treatment of advanced pancreatic neuroendocrine tumors","volume":"38","author":"Chen","year":"2024","journal-title":"Journal of China-Japan Friendship Hospital"},{"key":"key20241202101942_b32-ol-29-1-14795","first-page":"238","article-title":"Efficacy analysis of Traditional Chinese Medicine Combined with Somatostatin Analogues in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors","volume":"22","author":"Li","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"key20241202101942_b33-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/cancers13071701","article-title":"Targeted cancer therapy: What's new in the field of neuroendocrine neoplasms?","volume":"13","author":"Salvia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20241202101942_b34-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20241202101942_b35-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"key20241202101942_b36-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.3390\/cancers13246368","article-title":"Liver-directed therapy for neuroendocrine metastases: From interventional radiology to nuclear medicine procedures","volume":"13","author":"Cazzato","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20241202101942_b37-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000507194","article-title":"Liver embolisation for patients with neuroendocrine neoplasms: Systematic review","volume":"111","author":"Kanabar","year":"2021","journal-title":"Neuroendocrinology"},{"key":"key20241202101942_b38-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur J Radiol"},{"key":"key20241202101942_b39-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","article-title":"Intra-arterial therapy of neuroendocrine tumour liver metastases: Comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model","volume":"27","author":"Minh","year":"2017","journal-title":"Eur Radiol"},{"key":"key20241202101942_b40-ol-29-1-14795","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J Hepatol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:19:51Z","timestamp":1733127591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,8]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14795","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"article-number":"49"}}